Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

2026 data Public-data reference. official source

Type 2 Diabetes Mellitus

Open-data reference.

123 US clinical trials · 15 currently recruiting

Active & Recent Trials

RECRUITING 50,000 participants

An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

Bayer

NCT06278207

RECRUITING Phase 3 1,600 participants

A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes

Hoffmann-La Roche

NCT07351058

RECRUITING Phase 3 685 participants

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Prokidney

NCT05099770

RECRUITING NA 400 participants

GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

Medtronic Diabetes

NCT07228117

RECRUITING NA 264 participants

Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

Endogenex

NCT06267391

RECRUITING Phase 2 240 participants

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

Hoffmann-La Roche

NCT07112872

RECRUITING NA 216 participants

The GRoceries Aimed at Increasing Nutrition Study

University of Pennsylvania

NCT07167004

RECRUITING NA 100 participants

Preventing Type 2 Diabetes in Black Emergent Adult

University of North Carolina, Chapel Hill

NCT06848244

RECRUITING 100 participants

Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)

Petter Bjornstad

NCT05008276

RECRUITING Phase 2 100 participants

Regulation of Endogenous Glucose Production by Central KATP Channels

Meredith Hawkins

NCT03540758

RECRUITING Phase 1 70 participants

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

Amgen

NCT07160257

RECRUITING 60 participants

The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System

Joslin Diabetes Center

NCT05754281

RECRUITING Phase 2 60 participants

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Yale University

NCT05067621

RECRUITING Phase 1 22 participants

A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

Eli Lilly and Company

NCT06362265

RECRUITING 20 participants

A Study of Glycemic Control in Left Ventricular Assist

Mayo Clinic

NCT05933161

ACTIVE NOT RECRUITING 150,000 participants

An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States

Bayer

NCT06608212

ACTIVE NOT RECRUITING 4,500 participants

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

Bayer

NCT05348733

ACTIVE NOT RECRUITING 395 participants

Elucidation of Breast Milk Composition and Structure Over the First Year of Lactation: UC Davis Lactation Study

University of California, Davis

NCT01817127

ACTIVE NOT RECRUITING Phase 4 92 participants

Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism

VA Office of Research and Development

NCT03887936

ACTIVE NOT RECRUITING NA 70 participants

Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes

Baltimore VA Medical Center

NCT01176578

ACTIVE NOT RECRUITING NA 69 participants

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

University of Pittsburgh

NCT01047735

ACTIVE NOT RECRUITING NA 40 participants

Impact of Metabolic Health on Sperm Epigenetic Marks in Humans

Joslin Diabetes Center

NCT03860558

ACTIVE NOT RECRUITING NA 40 participants

An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes

Insulet Corporation

NCT07276776

ACTIVE NOT RECRUITING Early Phase 1 28 participants

GLP-1 and Hypoglycemia

University of Maryland, Baltimore

NCT01858896

ACTIVE NOT RECRUITING NA 15 participants

Is the Degree of Perceived Effort During Resistance Exercise Important for Improvements in Blood Glucose

University of New Mexi

NCT06208189

COMPLETED 96,759 participants

Impact of Medicaid Health Home on Patients With Diabetes in New York City

Icahn School of Medicine at Mount Sinai

NCT02713321

COMPLETED 6,000 participants

Improving Diabetes in Primary Care (IMPACT)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00108927

COMPLETED Phase 3 2,734 participants

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Novo Nordisk A/S

NCT06065540

COMPLETED Phase 3 2,639 participants

Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

Takeda

NCT00856284

COMPLETED Phase 3 1,912 participants

Study of Rivoglitazone in Type 2 Diabetes Mellitus

Daiichi Sankyo

NCT00484198

COMPLETED Phase 2 1,664 participants

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

Bayer

NCT05254002

COMPLETED 1,297 participants

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

AstraZeneca

NCT00229658

COMPLETED 1,123 participants

Detection of Ischemia in Asymptomatic Diabetics

Yale University

NCT00769275

COMPLETED Phase 4 949 participants

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

Gilead Sciences

NCT01425359

COMPLETED Phase 3 878 participants

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Sanofi

NCT01676220

COMPLETED Phase 3 650 participants

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

AstraZeneca

NCT02551874

COMPLETED Phase 2 593 participants

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

PhaseBio Pharmaceuticals

NCT01658501

COMPLETED Phase 3 571 participants

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

Lexicon Pharmaceuticals

NCT03285594

COMPLETED NA 536 participants

Mi Puente: My Bridge to Better Cardiometabolic Health and Well-Being

Scripps Whittier Diabetes Institute

NCT02723019

COMPLETED Phase 3 497 participants

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

AstraZeneca

NCT00736879

COMPLETED Phase 3 406 participants

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Hanmi Pharmaceutical Company Limited

NCT03353350

COMPLETED Phase 3 357 participants

Welchol as Monotherapy for Type 2 Diabetes Mellitus

Daiichi Sankyo

NCT00789737

COMPLETED NA 317 participants

Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics

Medtronic Diabetes

NCT04436822

COMPLETED Phase 2 299 participants

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Lexicon Pharmaceuticals

NCT01376557

COMPLETED NA 265 participants

Medical Care, Education, Social Support, And Goal-setting to Empower Self-management for Diabetes

University of Chicago

NCT03487692

COMPLETED Phase 2 259 participants

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

TWi Biotechnology

NCT01276106

COMPLETED Phase 3 254 participants

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

AstraZeneca

NCT00877890

COMPLETED Phase 2 246 participants

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

Novartis

NCT01068860

COMPLETED Phase 4 236 participants

Colesevelam for Children With Type 2 Diabetes

Daiichi Sankyo

NCT01258075

COMPLETED Phase 2 229 participants

An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial

Mannkind Corporation

NCT00754624

COMPLETED NA 211 participants

REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes

Massachusetts General Hospital

NCT02320253

COMPLETED Phase 2 206 participants

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

Pfizer

NCT02554877

COMPLETED Phase 2 186 participants

A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes

vTv Therapeutics

NCT01665352

COMPLETED NA 182 participants

The Efficacy and Treatment Adherence With an Integrated Program on HbA1c Scores in Patients With Type 2 Diabetes

KRJG Services

NCT01626053

COMPLETED NA 182 participants

Integrating Depression Services Into DM Management

University of Pennsylvania

NCT01098253

COMPLETED Phase 4 176 participants

University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)

University of Florida

NCT00994682

COMPLETED Phase 3 166 participants

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Merck Sharp & Dohme

NCT04029480

COMPLETED Phase 1 150 participants

Ginkgo Biloba Extract and the Insulin Resistance Syndrome

National Center for Complementary and Integrative Health (NCCIH)

NCT00032474

COMPLETED Phase 2 148 participants

A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Ligand Pharmaceuticals

NCT02851849

COMPLETED Phase 4 140 participants

Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00212290

COMPLETED Phase 2 121 participants

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

Response Pharmaceuticals

NCT02434744

COMPLETED Phase 4 108 participants

Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

Massachusetts General Hospital

NCT03818581

COMPLETED NA 104 participants

Physical Activity and Participation

VA Office of Research and Development

NCT02268916

COMPLETED NA 100 participants

Long Term Free Living Study With Modified Foods and Type 2 Diabetics

Johns Hopkins Bloomberg School of Public Health

NCT00198913

COMPLETED Phase 1 98 participants

4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

Pfizer

NCT03538743

COMPLETED NA 90 participants

Exercise Training and Glucose Metabolism in Aging

US Department of Veterans Affairs

NCT00701051

COMPLETED Phase 2 90 participants

Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

Wellstat Therapeutics

NCT00110851

COMPLETED NA 88 participants

Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes

Joslin Diabetes Center

NCT01073020

COMPLETED Phase 1 86 participants

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A

Hanmi Pharmaceutical Company Limited

NCT01724814

COMPLETED Phase 1 84 participants

A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

Pfizer

NCT02211261

COMPLETED Phase 2 83 participants

A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease

Prokidney

NCT02836574

COMPLETED NA 76 participants

Dance Dance Revolution (DDR) in Type 2 Diabetes

Charles Drew University of Medicine and Science

NCT00851019

COMPLETED Phase 4 71 participants

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

Ildiko Lingvay

NCT01505673

COMPLETED NA 69 participants

A Trial to Assess Steviol Glycosides on Acute Appetite Hormone Release

Midwest Center for Metabolic and Cardiovascular Research

NCT05287906

COMPLETED Phase 1 66 participants

A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions

Sanofi

NCT03776227

COMPLETED Phase 1 65 participants

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

AstraZeneca

NCT00894322

COMPLETED Phase 2 60 participants

Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus

Brigham and Women's Hospital

NCT00762671

COMPLETED NA 60 participants

Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)

State University of New York at Buffalo

NCT02722499

COMPLETED NA 57 participants

Effect of Diabetes Mellitus on Cholesterol Metabolism

Medical College of Wisconsin

NCT00879710

COMPLETED Phase 3 57 participants

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

Baylor Research Institute

NCT02251431

COMPLETED NA 50 participants

Grocery Prescription Program for Medicaid Adults With Hypertension or Type 2 Diabetes

Alison Gustafson

NCT06033664

COMPLETED Phase 1 48 participants

TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus

Takeda

NCT02430870

COMPLETED NA 47 participants

Yo Puedo! Diabetes Self-Management Education + mHealth in Mexico City

Yale University

NCT03159299

COMPLETED NA 45 participants

Diabetes Prevention and Control in the Workplace: A Pilot Study

State University of New York - Upstate Medical University

NCT00739336

COMPLETED Phase 1 41 participants

Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1

The University of Texas Health Science Center at San Antonio

NCT03560323

COMPLETED Phase 4 36 participants

Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients

St. Paul Heart Clinic

NCT00123643

COMPLETED Phase 1 36 participants

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

GlaxoSmithKline

NCT00559884

COMPLETED Phase 2 35 participants

Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

Daiichi Sankyo

NCT00361153

COMPLETED Phase 1 34 participants

Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus

Shionogi

NCT01154348

COMPLETED Phase 2 33 participants

Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes

Pacira Pharmaceuticals

NCT02762370

COMPLETED 30 participants

Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes

Rocky Mountain Diabetes and Osteoporosis Center

NCT01341067

COMPLETED Phase 2 30 participants

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

AstraZeneca

NCT00241423

COMPLETED Phase 1 30 participants

A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

AstraZeneca

NCT02367066

COMPLETED Phase 1 30 participants

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

AstraZeneca

NCT00904176

COMPLETED Phase 1 29 participants

A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function

GlaxoSmithKline

NCT00501462

COMPLETED NA 26 participants

Antioxidant Effects of Pomegranate Juice Versus Placebo in Adults With Type 2 Diabetes Mellitus

University of Colorado, Denver

NCT00668954

COMPLETED Phase 4 25 participants

Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?

Baylor College of Medicine

NCT01040819

COMPLETED Phase 1 25 participants

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

Gilead Sciences

NCT01546558

COMPLETED Early Phase 1 25 participants

Determinants of Diabetes Remission After Gastric Bypass Surgery

Blandine Laferrere

NCT02287285

COMPLETED Phase 1 24 participants

A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects

Sanofi

NCT03376802

Phase Distribution

PhaseTrial count
Early Phase 1 28
Phase 2 23
Phase 3 16
Phase 4 10

Top Sponsors

AstraZeneca 11 trials
Bayer 4 trials
Daiichi Sankyo 4 trials
Sanofi 4 trials
Gilead Sciences 3 trials
Pfizer 3 trials
Yale University 3 trials
GlaxoSmithKline 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Type 2 Diabetes Mellitus Trial Landscape

ClinicalTrials.gov lists 123 US studies indexed under Type 2 Diabetes Mellitus, and 15 of those are currently open to recruitment — roughly 12% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Type 2 Diabetes Mellitus shows 26 late-stage studies (Phase 3 and Phase 4 combined) alongside 51 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Type 2 Diabetes Mellitus is led by AstraZeneca with 11 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 100 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Type 2 Diabetes Mellitus?

PlainTrial tracks 123 US clinical trials for Type 2 Diabetes Mellitus, of which 15 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Type 2 Diabetes Mellitus?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →